[ Pharmaceutical Sciences Asia - ONLINE ]
Print ISSN 2586-8195 E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: https://doi.org/10.14456/mujps.2017.3Pharm Sci Asia 2017; 44(1), 32-39
 

Bioequivalence study of diacerein 50 mg capsules in healthy Vietnamese volunteers

G.T.H. Nguyen*, N.T.A. Le, H.T.T. Tran, V.N. Nguyen

- Institute of Drug Quality Control - Ho Chi Minh City, 200 Cobac Street, District 1, Ho ChiMinh City, Vietnam


Diacerein is chemically 4, 5-diacetyloxy-9, 10-dioxo-anthracene-2-carboxylic acid and is a disease modifying antirheumatoid drug used in the treatment of Osteoarthritis and chronic inflammatory arthritis. Diacerein is entirely converted into its active metabolite rhein (4,5-dihydroxy - 9,10-dioxoan thracene-2-carboxylic acid) before reaching the systemic circulation. This drug is administered orally as 50 mg twice daily and the the therapeutic concentration of rhein in blood plasma changes in a wide range of 1-10000 ng/mL, so a highly sensitive and accurate HPLC method was developed to quantify rhein in human plasma. This method successfully applied to the bioequivalence study of two formulations of diacerein 50 mg in healthy Vietnamese populations. After dosing, serial blood samples were collected for a period of 24 hrs. The power of all primary pharmacokinetic parameters were greater than 80 % indicating that the number of subjects was enough to confirm the bioequivalence of two formulations. No subject withdrew from our study, and no adverse events were found on analysis of vital signs or laboratory test results during the study. No abnormalities were found in clinical or biochemical parameters when comparing baseline versus end-of-study assessments. The 90% confidence intervals for the ratios of Cmax (93.43 % - 102.80%), AUC0-t (90.17 % - 113.76%) and AUC0-∞ (90.48 % - 113.32%) suggested that a single dose of the test and reference formulations of diacerein met the FDA regulatory requirements of bioequivalence.


Keyword:





Download full paper (PDF File size: 893.89 KB.)





Vol.44
No.4
October - December 2017

See other volume

 


Vol.44
No.3
July - September 2017

See other volume

 


Vol.44
No.2
April - June 2017

See other volume

 


Vol.44
No.1
January - March 2017

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register



    Copyright © 2017
    Faculty of Pharmacy, Mahidol University, THAILAND